Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 4/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475848 | 0.97 | CTSL (0.41) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL7422742 | 0.88 | L3MBTL1 (0.53) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL14243701 | 0.84 | L3MBTL1 (0.51) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL15684087 | 0.84 | L3MBTL1 (0.51) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL1915659 | 0.82 | CTSL (0.51) | CTSLPKMPPARA | |
| SCHEMBL1915662 | 0.82 | CTSL (0.51) | CTSLPKMPPARA | |
| SCHEMBL17756152 | 0.81 | PPARA (0.49) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL2410585 | 0.81 | PPARA (0.49) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL2410580 | 0.81 | PPARA (0.49) | L3MBTL1MMP3MMP8MMP9MMP1 | |
| SCHEMBL17755918 | 0.76 | L3MBTL1 (0.46) | L3MBTL1MMP3MMP8MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED | 2002-04-04 | — | — | US | disclosed |
| US-6251913-B1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
| US-6242615-B1 | AMIDATION OF ACID CONTAINING COMPOUNDS; USEFUL IN INHIBITING TUMOR NECROSIS FACTOR AND METALLOPROTEINASES | ZENECA LIMITED (GB) | 2001-06-05 | — | — | US | disclosed |
| EP-0971881-A1 | PROCESS FOR THE PREPARATION OF N-(3-HYDROXY-SUCCINYL)-AMINO ACID DERIVATIVES | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998043946-A1 | PROCESS FOR THE PREPARATION OF N-(3-HYDROXY-SUCCINYL)-AMINO ACID DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | MMP1, HCAR1, MMP13 | L3MBTL1 3013/4885MMP3 6/4885MMP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.